Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research is a clinical-stage biopharmaceutical company focused on developing a practice-changing treatment for depression, with a primary focus on patients with Treatment-Resistant Depression (TRD). They currently have two product candidates in their portfolio, GH001 and GH002, both of which are in clinical trials. The company's balance sheet strengthened in the first quarter of 2026, and they raised an additional $111.2 million in net proceeds through an underwritten offering in April, providing them with pro forma liquidity of approximately $378.5 million. Phase 2b data for GH001 was published in a peer-reviewed journal, providing validation for the product's potential, and the company has made significant progress in Phase 3-enabling work, including completing enrollment in a Phase 1 trial and selecting doses for the global Phase 3 pivotal program. GH Research also has strong intellectual property protections in place, with multiple patents pending for novel uses and compositions of their product candidates. While the biotech industry can be complex and competitive, GH Research's differentiated profile, including its proprietary aerosol delivery device and 11-minute median psychoactive duration, and recent positive data and operational updates indicate that they are on track to move their product candidates forward towards regulatory approval.

Bears say

GH Research is heavily focused on the development of its lead product, GH001, a inhalable form of the psychoactive drug 5-MeO-DMT, and has deferred its preparations for Phase 1 trials for its other product, GH002, suggesting a lack of confidence in its success. Additionally, although the company has generated buzz within the psychiatry community, there is a lack of concrete evidence to support widespread commercial adoption. The company's financials may appear strong, with $267M in cash and a reported earnings increase, but its plans for outer-year adoption are based on assumptions and do not accurately reflect the uncertain nature of the psychiatric field.

GHRS has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Buy based on their latest research and market trends.

According to 7 analysts, GHRS has a Buy consensus rating as of Jul 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.